The role of the androgen receptor in the development and progression of bladder cancer

Japanese Journal of Clinical Oncology

Volumn 42, Issue 7, 2012, Pages 569-577

  Li, Yi ^a,b   Izumi, Koji ^a   Miyamoto, Hiroshi ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Androgen receptor; Androgens; Bladder cancer; Carcinogenesis; Progression

Indexed keywords

5ALPHA ANDROSTAN 3 ONE; ANDROGEN RECEPTOR; BCG VACCINE; BETA CATENIN; CASPASE 3; CASPASE 7; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN D1; CYTOCHROME P450 4B1; E1A ASSOCIATED P300 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FINASTERIDE; GELATINASE B; GLUCURONOSYLTRANSFERASE; INTERLEUKIN 6; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PROTEIN BCL XL; PROTEIN KINASE B; SMALL INTERFERING RNA; STEROID 5ALPHA REDUCTASE; STEROID RECEPTOR COACTIVATOR 3; TESTOSTERONE; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE E3;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER DYSFUNCTION; CANCER GRADING; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DISEASE COURSE; DISEASE FREE SURVIVAL; EMBRYO DEVELOPMENT; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENOTOXICITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; CASTRATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INCIDENCE; MALE; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ANDROGEN; RISK FACTORS; SEX FACTORS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84864329579     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys072     Document Type: Article

References (70)

1. Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010;28:409-28.
2. Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int 2010;60:1-8.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
5. Wu X-R. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713-25.
6. Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27:295- 300.
7. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
8. Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009;115:68-74.
9. Hartge P, Harvey EB, Linehan WM, et al. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 1990;82:1636-40.
10. Hemelt M, Yamamoto H, Cheng KK, Zeegers MPA. The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses. Int J Cancer 2009;124:412-9.
11. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
12. Miyamoto H, Messsing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61:332-53.
13. Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 2004;10:2208-19.
14. Rosenzweig BA, Bolina PS, Birch L, Moran C, Marcovici I, Prins GS. Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit. Neurourol Urodyn 1995;14:87-96.
15. Pelletier G. Localization of androgen and estrogen receptors in rat and primate tissues. Histol Histopathol 2000;15:1261-70.
16. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987;8:1-28.
17. Wilson CM, McPhaul MJ. A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol Cell Endocrinol 1996;120:51-7.
18. Salmi S, Santti R, Gustafsson JA, Makela S. Co-localization of androgen receptor with estrogen receptor beta in the lower urinary tract of the male rat. J Urol 2001;166:674-7.
19. Celayir S, Ilçe Z, Dervisoglu S. The sex hormone receptors in the bladder in childhood-I: preliminary report in male subjects. Eur J Pediatr Surg 2002;12:312-7.
20. Keast JR. The autonomic nerve supply of male sex organs-an important target of circulating androgens. Behav Brain Res 1999;105:81-92.
21. Hall R, Andrews PL, Hoyle CH. Effects of testosterone on neuromuscular transmission in rat isolated urinary bladder. Eur J Pharmacol 2002;449:301-9.
22. Purves-Tyson TD, Arshi MS, Handelsman DJ, Cheng Y, Keast JR. Androgen and estrogen receptor-mediated mechanisms of testosterone action in male rat pelvic autonomic ganglia. Neuroscience 2007;148:92-104.
23. Madeiro A, Gira{ogonek}o M, Sartori M, Acquaroli R, Baracat E, Rodrigues De Lima G. Effects of the association of androgen/estrogen on the bladder and urethra of castrated rats. Clin Exp Obstet Gynecol 2002;29:117-20.
24. Filippi S, Morelli A, Sandner P, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-29.
25. Juan Y-S, Onal B, Broadaway S, et al. Effect of castration on male rabbit lower urinary tract tissue enzymes. Mol Cell Biochem 2007;301:227-33.
26. Zhang Y, Chen J, Hu L, Chen Z. Androgen deprivation induces bladder histological abnormalities and dysfunction via TGF-b in orchiectomized mature rats. Tohoku J Exp Med 2012;226:121-8.
27. Litman HJ, Bhasin S, O'Leary MP, Link CL, McKinlay JB. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU Int 2007;100:321-6.
28. Holmäng S, Mårin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993;23:99-106.
29. Yassin AA, El-Sakka AI, Saad F, Gooren LJ. Lower urinary-tract symptoms and testosterone in elderly men. World J Urol 2008;26:359-64.
30. Chen F, Langenstroer P, Zhang G, Iwamoto Y, See WA. Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines. J Urol 2003;170:2009-13.
31. Miyamoto H, Yang Z, Chen Y-T, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007;99:558-68.
32. Johnson AM, O'Connell MJ, Miyamoto H, et al. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urol 2008;8:7.
33. Boorjian SA, Heemers HV, Frank I, et al. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer 2009;16:123-37.
34. Kauffman EC, Robinson BD, Downes MJ, et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 2011;50:931-44.
35. Laor E, Schiffman ZJ, Braunstein JD, et al. Androgen receptors in bladder tumors. Urology 1985;25:161-3.
36. Noronha RF, Rao BR. Sex hormone receptors in localized and advanced transitional cell carcinoma of urinary tract in humans. Urology 1986;28:401-3.
37. Kirkali Z, Cowan S, Leake RE. Androgen receptors in transitional cell carcinoma. Int Urol Nephrol 1990;22:231-4.
38. Zhuang Y-H, Bläuer M, Tammela T, Tuohimaa P. Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology 1997;30:556-62.
39. Birtle AJ, Freeman A, Munson P. The androgen receptor revisited in urothelial carcinoma. Histopathology 2004;45:98-9.
40. Boorjian S, Ugras S, Mongan NP, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004;64:383-8.
41. Tuygun C, Kankaya D, Imamoglu A, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 2011;29:43-51.
42. Mir C, Shariat SF, van der Kwast TH, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int 2011;108:24-30.
43. Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 2012 (in press).
44. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008;21:S8-15.
45. Rau K-M, Chen Y-J, Sun M-T, Kang H-Y. Prognostic effects and regulation of activin A, maspin, and the androgen receptor in upper urinary tract urothelial carcinoma. Anticancer Res 2011;31:1713-20.
46. Niu Y, Altuwaijri S, Yeh S, et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA 2008;105:12188-93.
47. Enkelmann A, Heinzelmann J, von Eggeling F, et al. Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer. J Cancer Res Clin Oncol 2011;137:751-9.
48. Niu HT, Yang CM, Jiang G, et al. Cancer stroma proteome expression profile of superficial bladder transitional cell carcinoma and biomarker discovery. J Cancer Res Clin Oncol 2011;137:1273-82.
49. Cheng L, MacLennan GT, Pan C-X, et al. Allelic loss of the active X chromosome during bladder carcinogenesis. Arch Pathol Lab Med 2004;128:187-90.
50. Teng X-Y, Liu G-Q, Diao X-L, et al. CAG repeats in the androgen receptor gene are shorter in patients with pulmonary, esophageal or bladder carcinoma and longer in women with uterine leiomyoma. Oncol Rep 2010;23:811-8.
51. Liu CH, Huang JD, Huang SW, et al. Androgen recpetor gene polymorphism may affect the risk of urothelial carcinoma. J Biomed Sci 2008;15:261-9.
52. Heemers HV, Schmidt LJ, Kidd E, Raclaw KA, Regan KM, Tindall DJ. Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells. Prostate 2010;70:959-70.
53. Luo J-H, Xie D, Liu M-Z, et al. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival. Int J Cancer 2008;122:2554-61.
54. Ohtani M, Kakizoe T, Nishio Y, et al. Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 1986;46:2001-4.
55. Izumi K, Zheng Y, Hsu J-W, Chang C, Miyamoto H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinog 2012 (in press).
56. Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer 1972;8:587-94.
57. Okajima E, Hiramatsu T, Iriya K, Ijuin M, Matsushima S. Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol Res 1975;3:73-9.
58. Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y, Takenaka T. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol 1997;31:360-4.
59. Saikawa S, Kanamura H, Noriki S, Matsukawa S, Okada K. The effects of organ resection on rat urinary bladder carcinogenesis. Urol Res 2001;29:210-5.
60. Reid LM, Leav I, Kwan PW, Russell P, Merk FB. Characterization of a human, sex steroid-responsive transitional cell carcinoma maintained as a tumor line (R198) in athymic nude mice. Cancer Res 1984;44:4560-73.
61. Yang Z, Chang Y-J, Yu I-C, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007;13:348-53.
62. Imaoka S, Yoneda Y, Sugimoto T, et al. Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcription-polymerase chain reaction. Cancer Lett 2001;166:119-23.
63. Zheng Y, Izumi K, Yao JL, Miyamoto H. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer 2011;18:451-64.
64. Wu J-T, Han B-M, Yu S-Q, Wang H-P, Xia S-J. Androgen receptor is a potential therapeutic target for bladder cancer. Urology 2010;75:820-7.
65. Izumi K, Zheng Y, Zaengle J, Li Y, Miyamoto M. Epidermal growth factor induces bladder cancer cell proliferation through activation of androgen receptor. J Urol 2012;184(Suppl):e431.
66. Zhai Z, Wang Z, Fu S, et al. Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer. Gene Ther 2012 (in press).
67. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004;40:56-63.
68. Kastritis E, Murray S, Kyriakou F, et al. Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int J Cancer 2009;124: 103-8.
69. Li Y, Zheng Y, Izumi K, Ye B, Li F, Miyamoto H. Androgen activates b-catenin signaling in androgen receptor-positive bladder cancer cells. J Urol 2012;184(Suppl):e228.
70. Miyamoto H, Zheng Y, Izumi K. Nulcear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Curr Cancer Drug Tar 2012;12:14-22.